Gevo stock roars 230% on billion dollar renewable energy deal – Does YIG see value?

Gevo Incorporated (NASDAQ: GEVO) walked up the stock market podium to announce its largest renewable energy contract in history. The news instantly ignited a buying frenzy on Wall Street. Investors who missed Thursday’s boat are wondering whether the Friday boat will bring them a capital gain. However, investor optimism receives considerable criticism from the bears […]

SPAQ surges 30% as the hedge funds buy in before Fisker merger – Does YIG see value?

Spartan Energy Acquisition (NYSE: SPAQ), soon to be merging with Fisker, is the new EV kid on the block. While SPAQ is relatively fresh on the scene, its meteoric rise mirrors that of EV controversy Nikola Motors. However, the SPAQ momentum is starting to find a more sustainable equilibrium. Because after the Fisker merger announcement, […]

Johnson & Johnson set to acquire Momenta Pharmaceuticals – here’s what investors need to know

Johnson & Johnson announced this morning that they have entered a “definitive agreement” to acquire Momenta Pharmaceuticals at $52.50 per share. The acquisition has been confirmed as an all-cash transaction, which has been approved “unanimously” by the Board of Directors from both J&J and Momenta. The acquisition is set to be finalised later this year, […]

Genius Brands set to surge off Q2 earnings – here’s what you need to know

Genius Brands’ (NASDAQ: GNUS) Q2 earnings are generating significant noise on Wall Street. Some investors agree with the management and are proclaiming the results were impressive. At the same time, bearish investors are exposing the flaws in the financial reports, in particular dilution issues. The polarising entertainment company is down 80% in the past two […]

After rising 50% on Friday is Mesoblast now a good investment ahead of COVID-19 trials?

Mesoblast (ASX: MSB) (NASDAQ: MESO) was on our portfolio since May. However, volume started to climb higher this week as an advisory committee voted in favour of Mesoblasts pediatric drug remestemcel-L (Rynocil). The positive catalyst triggered a Mesoblast buying party on the ASX and the NASDAQ. For now, investors are optimistic about Mesoblast’s medium-long term […]

CureVac the newest vaccine contender on Wallstreet – here’s everything you need to know

CureVac’s (NASDAQ:CVAC) initial public offering in the US markets went incredibly well for investors, posting a 250% gain on its first day of trading. CureVac is a German Biopharma, based in Tübingen who specialises in the development of vaccines for infectious diseases. CVAC’s IPO raised $213.3 million USD in funding at its short price of […]

SHLL jumps 15% as the smart money pours in – does YIG see value?

Tortoise Acquisition Group (NYSE: SHLL) first attracted the wallets of Wall Street when they announced their intention to acquire EV company Hyliion. The hype started to die down as the SHLL merger is still another month away. However, today Tortoise Acquisition surged 15% on what seems to be no news. Bullish investors hold their finger […]

Cisco falls on strong Q4 earnings – here’s everything you need to know

You might know Cisco Systems (NASDAQ: CISCO) as the alive dinosaur in the IT and network world. Cisco’s strong Q4 earnings reaffirm its king like status. However, their Q1 earnings guidance disappointed Wall Street. Some investors are confused as to whether or not to jump on the CSCO train. Because on the one hand you […]

U.S government orders 100 million doses of Moderna’s vaccine, yet insiders are selling – here’s what you need to know

Moderna (NASDAQ: MRNA), alongside Novavax, is running at full speed in the vaccine race. The Trump Administration’s recent agreement with Moderna to order 100 million doses adds to the argument that MRNA is at the front of the pack. While the announcement is a positive catalyst, investors are doubtful that we will see an enormous […]

Twilio rises 300% on cloud software hype – Does YIG see value?

Twilio (NYSE: TWLO) is the industry captain of cloud communications. A raging bull market and a digital economy drove the software company to unchartered territories. After the Twilio stock price rose, 300% investors were keen on buying shares. However, the recent 12% drop has made investors skeptical about whether a TWLO investment is worth it. […]

INO falls 8% ahead of today’s earnings – does YIG see value?

Inovio Pharmaceuticals (NASDAQ: INO) is probably the most controversial COVID-19 play of 2020. Some investors are incredibly bullish on the vaccine frontrunner claiming the stock will be near Novavax very soon. However, many investors are pessimistic about INO, claiming it is a COVID-19 star fizzling out. Initially, the bulls seemed to be right as INO […]

Workhorse Group set to release earnings this week – here’s what you need to know.

Workhorse Group Inc (NASDAQ: WKHS) is set to release Q2 Earnings on Monday morning before market open. The US electric vehicle manufacturer operates in both the automotive and aviation industry. WKHS is most commonly known for it’s innovative spin on pick-up trucks and transport vans. Since July, WKHS has seen an enormous surge in investor […]

Sorrento Therapeutics soars 10% from Jim Cramer’s bullish outlook – should investors avoid shorting SRNE?

Sorento Therapeutics (NASDAQ: SRNE) is causing Wall Street to divide. Some bears are adamant that Sorrento will become a COVID-19 stock that will fade in a few months. Whereas the bulls are aggressively buying up SRNE shares as they believe the biotech has not even come close to its true value. While the overall war […]